PuSH - Publikationsserver des Helmholtz Zentrums München

Sprinzl, M.F. ; Reisinger, F. ; Puschnik, A. ; Ringelhan, M. ; Ackermann, K. ; Hartmann, D.* ; Schiemann, M. ; Weinmann, A.* ; Galle, P.R.* ; Schuchmann, M.* ; Friess, H.* ; Otto, G.* ; Heikenwälder, M. ; Protzer, U.

Sorafenib perpetuates cellular anti-cancer effector functions by modulating the cross talk between macrophages and natural killer cells.

Hepatology 57, 2358-2368 (2013)
Verlagsversion Volltext DOI
Free by publisher
Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
BACKGROUND: Alternatively polarized macrophages (MΦ) shape the microenvironment of hepatocellular carcinoma (HCC) and temper anti-cancer immune responses. We investigated if Sorafenib alters the HCC microenvironment by restoring classical macrophage polarization and triggering tumor-directed NK cell responses. METHODS: In vivo experiments were conducted with Sorafenib (25 mg/kg) treated C57BL/6 wild-type as well as HBV and lymphotoxin transgenic mice with and without HCC. Monocyte derived MΦ or tumor-associated macrophages (TAM) isolated from HCC tissue were treated with Sorafenib (0.07-5.0 µg/ml) and co-cultured with autologous NK cells. MΦ and NK cell activation was analyzed by flow cytometry and killing assays, respectively. Cytokine and growth factor release was measured by ELISA. RESULTS: Short-term administration of Sorafenib triggered activation of hepatic NK cells in wild-type and tumor bearing mice. In vitro, Sorafenib sensitized MΦ to LPS reverting alternative MΦ polarization and enhanced IL12 secretion (P=0.0133). NK cells activated by Sorafenib-treated MΦ showed increased degranulation (15.3±0.2% vs. 32.0±0.9%, P<0.0001) and IFNγ secretion (2.1±0.2% vs. 8.0±0.2%, P<0.0001) upon target cell contact. Sorafenib-triggered NK cell activation was verified by co-culture experiments using TAM. Sorafenib-treated MΦ increased cytolytic NK cell function against K562, Raji and HepG2 target cells in a dose-dependent manner. Neutralization of IL12 or IL18 as well as inhibition of the NFκB pathway reversed NK cell activation in MΦ/NK co-cultures. CONCLUSION: Sorafenib triggers pro-inflammatory activity of TAM and subsequently induces anti-tumoral NK cell responses in a cytokine and NFĸB-dependent fashion. This observation is relevant for HCC therapy, as Sorafenib is a compound in clinical use, which reverses alternative polarization of TAM in HCC.
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter liver cancer; therapy; microenvironment; immunology; HCC; Colony-stimulating Factor ; Hepatocellular-carcinoma Patients ; Tumor-associated Macrophages ; Regulatory T-cells ; Ifn-gamma ; Human Monocytes ; Nk Cells ; Induced Apoptosis ; Interferon-gamma ; Factor-i
ISSN (print) / ISBN 0270-9139
e-ISSN 1527-3350
Zeitschrift Hepatology
Quellenangaben Band: 57, Heft: 6, Seiten: 2358-2368 Artikelnummer: , Supplement: ,
Verlag Wiley
Verlagsort Hoboken, NJ
Begutachtungsstatus Peer reviewed